Pd52-10 Oncologic Outcomes of Testosterone Therapy for Men on Active Surveillance for Prostate Cancer: A Population-Based Analysis

You have accessJournal of UrologySexual Function/Dysfunction: Medical, Hormonal & Non-surgical Therapy II (PD52)1 May 2024PD52-10 ONCOLOGIC OUTCOMES OF TESTOSTERONE THERAPY FOR MEN ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER: A POPULATION-BASED ANALYSIS Elie Kaplan-Marans, Tenny R. Zhang, and Jim C. Hu Elie Kaplan-MaransElie Kaplan-Marans , Tenny R. ZhangTenny R. Zhang , and Jim C. HuJim C. Hu View All Author Informationhttps://doi.org/10.1097/01.JU.0001009412.04863.1b.10AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: There is a lack of research on the effects of testosterone therapy in men with untreated prostate cancer. Our objective was to assess the effect of testosterone therapy on oncologic outcomes in men on active surveillance for prostate cancer. METHODS: Surveillance, Epidemiology, and End Results (SEER)-Medicare linked data was used to identify men diagnosed with prostate cancer from 2008 to 2017 that were managed with active surveillance who received testosterone (n=167) vs. no testosterone therapy (n=6,658). Outcomes included conversion from active surveillance to active treatment (radical prostatectomy, cryotherapy, radiation, or androgen deprivation therapy), prostate cancer-specific and overall mortality. Statistically significant factors in univariate analysis were incorporated into the Cox proportional hazard regression model for multivariate analysis. RESULTS: Of the 6,825 men, median age was 71 years (interquartile range IQR, 68-74) and 72 years (IQR, 69-75) in the testosterone and no testosterone therapy cohorts, respectively. Median follow-up after prostate cancer diagnosis was 5.2 years (IQR, 3.4-7.8) and 4.7 years (IQR, 3.2-6.9). There were zero prostate cancer-specific mortalities in the testosterone therapy cohort and 39 (0.6%) prostate cancer-specific mortalities in the no testosterone therapy cohort. Testosterone therapy was not associated with conversion to active treatment (HR 0.66, CI 0.46-0.97, p=0.033) or overall mortality (HR 1.02, CI 0.68-1.53, p>0.9). CONCLUSIONS: In the first population-based, nationally representative study of testosterone therapy in men on active surveillance, testosterone therapy did not increase the risk of conversion to active therapy or worsen mortality. Prospective studies are needed to confirm these findings. Download PPT Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e1076 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Elie Kaplan-Marans More articles by this author Tenny R. Zhang More articles by this author Jim C. Hu More articles by this author Expand All Advertisement PDF downloadLoading ...